{"id":46433,"date":"2025-11-12T15:07:31","date_gmt":"2025-11-12T07:07:31","guid":{"rendered":"https:\/\/flcube.com\/?p=46433"},"modified":"2025-11-12T15:07:32","modified_gmt":"2025-11-12T07:07:32","slug":"huadong-medicine-files-nda-for-roflumilast-cream-zoryve-first-pde%e2%80%914-topical-for-atopic-dermatitis-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46433","title":{"rendered":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted<\/strong> the company\u2019s <strong>New Drug Application (NDA)<\/strong> for <strong>Roflumilast Cream 0.15\u202f% (brand name ZORYVE)<\/strong>. The product is intended for the <strong>topical treatment of mild\u2011to\u2011moderate atopic dermatitis<\/strong> in patients <strong>6\u202fyears of age and older<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-licensing-structure\">Deal &amp; Licensing Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicant<\/strong><\/td><td>Huadong Medicine Co., Ltd. (000963.SZ)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Roflumilast Cream 0.15\u202f% \u2013 brand name <strong>ZORYVE<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Topical therapy for mild\u2011to\u2011moderate <strong>atopic dermatitis<\/strong> (\u2265\u202f6\u202fyr)<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA <strong>acceptance of NDA<\/strong> (12\u202fNov\u202f2025)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td><strong>Arcutis Biotherapeutics, Inc.<\/strong> (NASDAQ:\u202fARQT)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Sino\u2011American Huadong (wholly\u2011owned Huadong subsidiary)<\/td><\/tr><tr><td><strong>Geographic Rights<\/strong><\/td><td>Exclusive development, registration, manufacturing &amp; commercialization in <strong>Greater China<\/strong> (Mainland, Hong\u202fKong, Macau, Taiwan) and <strong>Southeast Asia<\/strong> (Indonesia, Singapore, Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, Vietnam)<\/td><\/tr><tr><td><strong>Launch Timeline<\/strong><\/td><td>Expected market authorization Q2\u202f2026; commercial launch in Greater China Q3\u202f2026, followed by staggered rollout across Southeast Asia through 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> <strong>Roflumilast<\/strong>, a highly potent, selective <strong>non\u2011steroidal phosphodiesterase\u20114 (PDE\u20114) inhibitor<\/strong>.<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> PDE\u20114 catalyzes the breakdown of cyclic AMP, driving the production of pro\u2011inflammatory cytokines while suppressing anti\u2011inflammatory mediators. Inhibition restores the cAMP balance, <strong>reducing skin inflammation<\/strong> and pruritus associated with atopic dermatitis.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Unlike topical steroids, ZORYVE offers a <strong>steroid\u2011free<\/strong> anti\u2011inflammatory option, potentially lowering the risk of skin atrophy and tachyphylaxis with long\u2011term use.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epidemiology:<\/strong> Atopic dermatitis affects <strong>\u2248\u202f15\u202f%<\/strong> of Chinese children and <strong>\u2248\u202f5\u202f%<\/strong> of adults, representing a <strong>$3.2\u202fbillion<\/strong> addressable market in Greater China alone.<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Current therapy relies heavily on topical corticosteroids and calcineurin inhibitors, both with safety or tolerability concerns for chronic use.<\/li>\n\n\n\n<li><strong>Revenue Forecast (Huadong):<\/strong> Assuming a 4\u202f% market share within three years of launch, projected <strong>annual sales of CNY\u202f1.1\u20131.4\u202fbillion<\/strong> (\u2248\u202fUS$150\u2013190\u202fmillion) in Greater China. Expansion into Southeast Asia could add an additional <strong>US$80\u2013110\u202fmillion<\/strong> by 2029.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory timelines, commercial launch expectations, and revenue projections for ZORYVE. Actual results may differ due to risks including clinical outcomes, regulatory approvals, market acceptance, competitive dynamics, and manufacturing scale\u2011up.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-ba686596-f2d7-434e-86e5-46d5388a20e1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ba686596-f2d7-434e-86e5-46d5388a20e1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46842,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,114,38,887],"class_list":["post-46433","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-huadong-medicine","tag-market-approval-filings","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46433\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46433\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T07:07:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-12T07:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China\",\"datePublished\":\"2025-11-12T07:07:31+00:00\",\"dateModified\":\"2025-11-12T07:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1201.webp\",\"keywords\":[\"Auto-immune\",\"Huadong Medicine\",\"Market approval filings\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46433#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46433\",\"name\":\"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1201.webp\",\"datePublished\":\"2025-11-12T07:07:31+00:00\",\"dateModified\":\"2025-11-12T07:07:32+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46433\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46433#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46433","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.","og_url":"https:\/\/flcube.com\/?p=46433","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T07:07:31+00:00","article_modified_time":"2025-11-12T07:07:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46433#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46433"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China","datePublished":"2025-11-12T07:07:31+00:00","dateModified":"2025-11-12T07:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46433"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46433#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","keywords":["Auto-immune","Huadong Medicine","Market approval filings","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46433#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46433","url":"https:\/\/flcube.com\/?p=46433","name":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46433#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46433#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","datePublished":"2025-11-12T07:07:31+00:00","dateModified":"2025-11-12T07:07:32+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that China\u2019s National Medical Products Administration (NMPA) has accepted the company\u2019s New Drug Application (NDA) for Roflumilast Cream 0.15\u202f% (brand name ZORYVE). The product is intended for the topical treatment of mild\u2011to\u2011moderate atopic dermatitis in patients 6\u202fyears of age and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46433#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46433"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46433#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","width":1080,"height":608,"caption":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46433#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) \u2013 First PDE\u20114 Topical for Atopic Dermatitis in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46433"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46433\/revisions"}],"predecessor-version":[{"id":46844,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46433\/revisions\/46844"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46842"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}